Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Study Completion Date

2023-06-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate low oxygen areas called hypoxia within tumors. These low oxygen areas are thought to be the reason why tumors are more resistant to chemotherapy and radiation treatment.

An imaging technique using a hypoxia tracer called fluoromisonidazole (FMISO) can detect low oxygen areas within a tumor. This imaging technique, called a PET scan, uses positively charged particles to detect slight changes in the body's biochemistry and metabolism. FMISO PET scans have been performed in patients with head and neck cancer and have shown the ability to detect low oxygen areas within tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

NCT00038038

Squamous Cell Carcinoma Head and Neck Neoplasms Metastases, Neoplasm

WITHDRAWN NA

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

NCT00559377

Cervical Adenocarcinoma Cervical Squamous Cell Carcinoma Stage IB Cervical Cancer +5 more

COMPLETED PHASE2

Feasibility of FMISO in Brain Tumors

NCT03649880

Malignant Brain Neoplasm

RECRUITING PHASE2

18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma

NCT01169350

Recurrent Adult Soft Tissue Sarcoma Stage I Adult Soft Tissue Sarcoma Stage II Adult Soft Tissue Sarcoma +2 more

TERMINATED PHASE2

Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer

NCT01235052

Cancer of Head and Neck Head and Neck Neoplasms

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 (closed to accrual)

Cohort 1 (closed to accrual) Cohort 1 (closed to accrual) There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy. This is currently one accepted standard of care. In a subcohort of patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/ CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.

Group Type EXPERIMENTAL

fluorine-18-labeled fluoro-misonidazole (18F-FMISO)

Intervention Type RADIATION

18F-FMISO PET scan

Intervention Type DEVICE

MRI

Intervention Type DEVICE

FDG PET/CT scan

Intervention Type DEVICE

Cohort 2 (closed to accrual)

Experimental: Cohort 2 (closed to accrual) Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-4 month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.

Group Type EXPERIMENTAL

fluorine-18-labeled fluoro-misonidazole (18F-FMISO)

Intervention Type RADIATION

18F-FMISO PET scan

Intervention Type DEVICE

MRI

Intervention Type DEVICE

FDG PET/CT scan

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluorine-18-labeled fluoro-misonidazole (18F-FMISO)

Intervention Type RADIATION

18F-FMISO PET scan

Intervention Type DEVICE

MRI

Intervention Type DEVICE

FDG PET/CT scan

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of head and neck carcinoma (excluding nasopharynx, paranasal sinus, salivary, and thyroid malignancies)Any unknown primary squamous cell carcinoma of head and neck with gross nodes is allowed (2002 AJCC)
* 18 years of age or older
* Must not have received prior radiation therapy or chemotherapy for this diagnosis. Patients who have had their primary site tumor removed by surgery but still present with grossly enlarged lymph nodes are eligible for this study.
* Karnofsky performance status ≥ 70.

Exclusion Criteria

* all nasopharyngeal, paranasal sinus, salivary cancer, and thyroid malignancies
* prior chemotherapy or radiotherapy within the last three years
* patients that underwent previous surgical resection for the same disease (except for biopsy or surgery removing primary site tumor but still present with grossly enlarged lymph nodes)
* any prior radiotherapy to the head and neck region
* pregnant (confirmed by serum b-HCG in women of reproductive age) or breast feeding

• Subjects with a known contraindication to the standard MRI contrast agent (Gadavist, a gadolinium-based contrast agent) and/or a recent estimated glomerular filtration rate (eGFR) of 30 or less will be excluded from all DCE-MRIs, and will instead receive non-contrast MRIs at the DCE-MRI time points.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No